Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 26;11:8921. doi: 10.1038/s41598-021-87959-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fc-GDF15 Mutant 2C (A3N/N5T/V98I) has improved weight loss efficacy in vivo. (a) Body weight change after a single subcutaneous dose of the indicated Fc-GDF15 variant or the wildtype Fc-GDF15 (Fc-WT) control. Dose, 0.5 mg/kg. n = 7–10 per group. Data are reported as mean ± SEM *P ≤ 0.05, **P ≤ 0.01 for Fc-GDF15 WT treatment as compared to all other treatments. Mixed effects model followed by Tukey’s post hoc test. (b) Daily food intake normalized to body weight following Fc-GDF15 treatment in (a). Data are reported as mean ± SEM; NS, P > 0.05. Mixed effects model followed by Tukey’s post hoc test. (c) Serum concentration of Fc-GDF15 variants on Day 14. Data are reported as mean ± SEM and analyzed with a pairwise Wilcoxon test. NS, P > 0.05.